



ANTEO EXTENDS ENTITLEMENT ISSUE OFFER PERIOD

For Immediate Release:

December 11, 2015

December 11 2015 – Anteo Diagnostics (ASX: ADO) (Anteo) wishes to advise that it will be extending the closing date for the acceptance of applications under the 1 for 5.35 non-renounceable Entitlement Issue (“Offer”), announced on 30 November 2015.

The closing date for the Offer is now 5pm AEDT on Monday, 21 December 2015.

The extension of the closing date, originally falling on 16 December 2015, has been made to give shareholders sufficient time to submit their Entitlement applications.

Dr Geoff Cumming, CEO of Anteo Diagnostics, commented, “The Anteo Board is pleased with how the funding package is progressing, however acknowledges the requests from some shareholders who require additional time to submit their applications. This extension is designed to provide maximum opportunity for those shareholders to participate in the lead up to Christmas.”

“We thank all those shareholders who have subscribed to date, and continue to encourage all shareholders to take up the offer,” finished Dr Cumming.

The revised timetable for the remaining Offer dates is set out below:

Closing Date for Entitlement Offer	Monday, 21 December 2015
Securities traded on a deferred settlement basis	Tuesday, 22 December 2015
Company to notify ASX of under subscriptions	Wednesday, 23 December 2015
Issue of New Shares pursuant to the Offer and deferred settlement trading ends. Company to confirm to ASX Appendix 3B	Tuesday, 29 December 2015
Trading on ASX of New Shares	Wednesday, 30 December 2015

For further information, see our website (www.anteodx.com) or contact the persons outlined below.

Company	Media and Investor Relations
Dr. Geoff Cumming, Chief Executive Officer T: + 61 7 3219 0085	Jane Lowe, IR Department E: jane.lowe@irdepartment.com.au T: + 61 411 117 774
Richard Martin, Chief Financial Officer T: + 61 7 417 229 810	

About Anteo Diagnostics

Anteo Diagnostics (ASX: ADO) is a global medical technology company, developing and commercialising products for sale into the lifesciences, in-vitro diagnostics, point of care, medical devices and bioseparations markets.

The Anteo group owns a patented nanogluce technology, which is used by healthcare customers as an addition to their existing tests, to consistently enable laboratory test results that can either be delivered faster, cheaper, or with greater specificity or sensitivity than incumbent tests.



anteo diagnostics

This nanoglue technology, called Mix&Go for healthcare markets, is starting to gain traction with the Company's target markets, due to its ability to revolutionise the way scientists work.

While Anteo is largely focused on the healthcare markets, the nanoglue technology also has potential for use in other areas, such as batteries. Early stage research is being conducted into the viability of this battery product.

For more information, please visit www.anteodx.com.

Anteo Diagnostics Limited ACN 070 028 625
Unit 4, 26 Brandl St, Eight Mile Plains, QLD 4113, Australia
p: +61 7 3219 0085 f: +61 7 3219 0553
contact@anteodx.com www.anteodx.com